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Abstract
Objective. To explore the influence of TNF inhibitor (TNFi) therapy and rituximab (RTX) upon the incidence
of cancer in patients with RA and prior malignancy.
Methods. The study population comprised RA subjects with a prior malignancy reported to the UK na-
tional cancer registers, recruited to the British Society for Rheumatology Biologics Register from 2001 to
2013. We compared rates of first incident malignancy in a TNFi cohort, RTX cohort and synthetic DMARDs
(sDMARD) cohort.
Results. We identified 425 patients with a prior malignancy from 18 000 RA patients in the study. Of
these, 101 patients developed a new malignancy. The rates of incident malignancy were 33.3 events/1000
person-years (py) in the TNFi cohort, 24.7 events/1000 py in the RTX cohort and 53.8 events/1000 py in
the sDMARD cohort. The age- and gender-adjusted hazard ratio was 0.55 (95% CI: 0.35, 0.86) for the
TNFi cohort and 0.43 (95% CI: 0.10, 1.80) for the RTX cohort in comparison with the sDMARDs cohort.
The 17.0% of patients in the sDMARDs cohort had a recurrence of the same cancer in comparison with
the 12.8% and the 4.3% in the TNFi and RTX cohorts, respectively.
Conclusions. Although numbers are still low, it seems that patients with RA and prior malignancy selected
to receive either a TNFi or RTX in the UK do not have an increased risk of future incident malignancy.
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Rheumatology key messages
. Patients with prior malignancy selected to receive biologics do not have an increased risk of incident malignancy.
. The time between past cancer and first biologic was shorter among rituximab than TNFi patients.
. It remains unknown whether biologics can be used safely in all patients with prior malignancy.
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Introduction
RA is characterized by chronic inflammation. A substantial
body of evidence supports the conclusion that chronic
inflammation can predispose an individual to cancer.
Chronic exposure to inflammatory mediators leads to
increased cell proliferation, mutagenesis, oncogene acti-
vation and angiogenesis. The longer the inflammation per-
sists, the higher the risk of associated carcinogenesis [1].
Data from several studies have suggested that the relative
risk of certain types of malignancy such as lymphoma,
leukaemia and lung cancer is increased in patients with
RA [2, 3]. Factors such as disease activity and severity,
and smoking have been recognized to increase the inci-
dence of malignancies in patients with RA [3]. The effects
of RA treatment on this risk remain less clear. Synthetic
DMARDs (sDMARDs), such as MTX and AZA, have been
linked to an increased risk of lymphoma whereas other
studies have not found increased rates of cancer in
sDMARD-treated patients [4].
TNF is one of the cytokines involved in the immunosur-
veillance of tumours and its inhibition may theoretically
increase the risk of either tumour development or in-
creased growth rate or malignant potential of established
tumours. Recent publications studying the risk associated
with TNF inhibitor (TNFi) have also not identified an in-
creased risk of cancer overall [57], although there have
been reports of increases in certain skin cancers (melan-
oma) [8, 9].
The majority of these meta-analyses and observational
studies of cancer risk have been undertaken among pa-
tients without a history of pre-existing cancer, and there-
fore cannot necessarily be extrapolated to patients with
this history prior to initiation of TNFi or other biologic
therapies. This has been addressed in part by two publi-
cations, which have looked at the risk associated with
TNFi therapy compared with sDMARD therapy. An ana-
lysis from the British Society for Rheumatology Biologics
Register (BSRBR)-RA [10] showed that the rate of incident
malignancy (IM) in patients with RA and prior malignancy
who receive an TNFi was not increased in comparison
with patients receiving sDMARDs after an average of 3
years follow-up. In this analysis, the age- and sex-ad-
justed incidence rate ratio was 0.58 (95% CI: 0.23, 1.43)
for the TNFi-treated cohort compared with the sDMARD
cohort. No significant association was also found in
the German RABBIT registry (German acronym for
Rheumatoid Arthritis  Observation of Biologic Therapy)
[11] with an incidence rate ratio of 1.4 (95% CI: 0.5, 5.5)
for the TNFi vs sDMARDS. Despite these reassuring re-
sults, both of these studies were small and only studied
cancer risk over the short term (23 years). Given the la-
tency of cancer, uncertainty about the use of TNFi in this
situation remains unclear.
Rituximab (RTX) was licensed for RA in 2006 in the UK
for use in TNFi inadequate responders. It had already
been licensed as a successful treatment for B cell lymph-
oma [12]. As such, there is generally less concern about
using this agent in patients with a history of cancer. The
British Society for Rheumatology (BSR) guidelines for RTX
did not include a warning regarding patients with past
cancer, and therefore RTX as first-line biologic treatment
outside of current licensed indications may be considered
by physicians in patients with this history. That said, data
on the risk of non-lymphoma malignancy among patients
receiving RTX remain sparse and often complicated by
previous exposure to TNFi [13, 14]. The aims of this
study, therefore, were to explore the influence of RTX on
the incidence of cancer in patients with RA and a prior
malignancy and to update our previous report on cancer
incidence in RA patients with prior malignancy treated
with a TNFi.
Methods
Patient population
Patients included in this study were participants in the
BSRBR-RA, which is a large national prospective obser-
vational cohort established primarily to assess the long-
term safety of exposure to biologic therapies in patients
with RA. Full details of the BSRBR-RA methodology have
been published previously [15]. In brief, the study com-
menced in 2001 with the goal to recruit and follow patients
with RA starting biologic therapies and compare these to
a group of patients with similar disease not receiving
these drugs to see if there were any differences in drug
safety. Recruitment to TNFi cohorts occurred between
2001 and 2008 and re-opened again in 2010 with the pri-
mary aim to recruit a contemporary comparison cohort for
the newer biologic therapies licensed in the UK.
Recruitment of patients starting RTX as a first biologic
occurred between 2008 and 2011. A comparison cohort
of biologic-naı¨ve patients with active RA defined as
DAS28> 4.2 was recruited in parallel. These patients
had active disease at the time of recruitment despite cur-
rent treatment with sDMARDs.
Ethical approval
Ethical approval for the BSRBR-RA was granted by the
North West Multi-Centre Research Ethics Committee in
December 2000. All patients provided written informed
consent. No additional approval was required for this spe-
cific analysis.
Patient selection
All patients with RA registered with the BSRBR-RA who
were commencing a TNFi or RTX as their first biologic
were eligible for inclusion in this analysis. A third cohort
of the patients from the BSRBR-RA who had never
received biologic agents was used for comparison.
Identification of prior malignancy
Analysis was limited to patients with prior malignancy,
defined as diagnosed prior to start of first biologic drug
(for the anti-TNF and RTX cohorts) or study registration
(for the sDMARD comparison group). At registration, all
patients were linked to the UK Health and Social Care
Service Information Centre (HSCIC), which collates man-
datory data from the eight regional English cancer
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registers, in addition to similar registers in Wales, Scotland
and Northern Ireland on the diagnosis of all malignancies
in the UK. This linkage provided details of all historic can-
cers, including date of diagnosis, type and anatomic site.
Carcinoma-in situ and non-melanoma skin cancer were
excluded, as capture of these malignancies is less com-
plete. Where patients had>1 prior malignancy, the most
recent malignancy was reported.
Capture of new malignancy diagnoses following
recruitment
Follow-up data, including changes to therapy and occur-
rence of serious adverse events were captured from the
rheumatology team (6-monthly for 3 years and then annu-
ally) and the patient (6-monthly for 3 years). In addition,
the linkage to the UK HSCIC also provides details (date
and ICD-10 code) on any new cancers diagnosed within
the cohort, although there can be a considerable delay
(around 18 months) [16] in reporting to the BSRBR-RA
while validation procedures are undertaken.
Definition of IM
IMs were defined as malignancies diagnosed after the first
dose of biologic therapy or after the study registration
date for the sDMARD cohort. New primaries, local recur-
rence and metastases were all included as incident can-
cers. Carcinoma-in situ and non-melanoma skin cancer
were excluded, as were benign cancers. Once cancers
were reported from any source, i.e. patient or HSCIC
report, clinicians were asked to provide further information
for these events in order to understand if there was any
relation to the prior cancer.
Statistical analysis
Follow-up time was calculated from the date of the first
TNFi or RTX use for the biologic cohorts, or from the regis-
tration date for the comparison cohort, to 31 May 2013,
first IM or the death date, whichever occurred first. Within
the TNFi cohort, patients could switch between different
TNFi. The biologic cohorts contributed person-years (py)
of follow-up even if the biologic therapy was stopped, but
only for the period of the patient being off any biologic
therapy. The follow-up was then censored at the initiation
of a second biologic with a different target. Malignancies
were attributed to biologic therapy irrespective of drug
discontinuation. Patients initially registered in the com-
parison cohort who subsequently received a TNFi or
RTX contributed person-years to the comparison cohort
up to the date that the biologic drug was started, and
contributed subsequent follow-up to the biologic cohort.
Crude incidence rates were calculated as the number of
first episodes of IM per 1000 py of follow-up with a 95%
CI. Survival analyses, performed using a Cox proportional
hazards model, were used to compare the rates of IM
between cohorts, adjusted for age and sex. All analyses
were conducted using Stata version 11 (StataCorp,
College Station, TX, USA). We performed a sensitivity ana-
lysis censoring all follow-up at 5 years to compensate for
the shorter follow-up of the RTX cohort.
Results
In total, 14 168 patients from the BSRBR-RA received a
TNFi as their first biologic. Of the 4179 patients in the
BSRBR-RA who ever received RTX, for this analysis we
selected the 257 who received it as their first biologic as
we aimed to explore the incidence of malignancies in pa-
tients receiving a first biologic. The comparison cohort
consisted of 3787 sDMARD-treated patients. After linkage
with the HSCIC, 425 patients with a prior history of malig-
nancy were identified: 243 (1.7%) of the 14 168 in the TNFi
cohort, 23 (8.9%) of the 257 in the RTX cohort and 159
(4.2%) in the comparison cohort. All subsequent analyses
were restricted to these patients.
The TNFi cohort was younger than the other two co-
horts and comprised proportionally more women. The
sDMARD cohort had less severe disease (Table 1). All
three groups were much older than the mean age previ-
ously reported in this cohort [56 (12)] [17]. Sites of most
recent prior malignancy were similar between cohorts with
>80% of patients in the three cohorts having had a solid
cancer, with the remainder divided into lymphoprolifera-
tive malignancies and melanomas. No patient with prior
melanoma received RTX. Proportionally more prior malig-
nancies were diagnosed>10 years before registration in
the TNFi cohort (56.8%) compared with the RTX cohort
(17.4%) and the comparison (37.1%) cohort.
The total follow-up time was 855 py for the sDMARD
cohort, 1591 py for the TNFi cohort and 81 py for the RTX
cohort. Patients in the RTX cohort contributed a median
follow-up time of 3.9 [interquartile range (IQR): 3.34.6]
years compared with 6.8 (IQR: 3.58.8) for patients in
the TNFi cohort and 6.6 (IQR: 4.47.8) for patients in the
sDMARD cohort.
Overall, there were 101 IMs: 46 in the sDMARD cohort,
53 in the TNFi cohort and 2 in the RTX cohort (Table 2).
The unadjusted hazard ratio (HR) was 0.51 (95% CI: 0.33,
0.79) for the TNFi-treated patients and 0.45 (95% CI: 0.11,
1.87) for the RTX-treated patients compared with the
sDMARD cohort.
A sensitivity analysis censored at 5 years of follow-up
(total time sDMARD: 609 py, TNFi 971 py, RTX 81 py)
identified 64 IMs: 36 in the sDMARD cohort, 26 in the
TNFi cohort and 2 in the RTX cohort (Table 2). The un-
adjusted HR was 0.45 (95% CI: 0.27, 0.75) for the
TNFi-treated patients and 0.42 (95% CI: 0.10, 1.75) for
the RTX-treated patients compared with the sDMARD
cohort, which did not differ substantially after adjustment
for age and gender.
Since smoking is a risk factor for many types of cancer,
a further adjustment analysis including the smoking status
was done to check its influence in the recurrence or diag-
nosis of new cancers. This adjustment did not significantly
change the HR for any of the biologic cohorts (Table 2).
Supplementary Table S1, available at Rheumatology
Online, shows the distribution of anatomical sites of
prior and incident malignancies. The most frequent prior
malignancy in the three cohorts was the breast cancer
followed by melanoma in the sDMARD and TNFi cohorts
and by lymphoma in the RTX cohort. In the sensitivity
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analysis, 5% (13/243) of TNFi-treated patients had recur-
rence of the prior malignancy (either locally or metastases)
compared with 4% (1/23) in the RTX cohort and 12% (19/
159) in the sDMARD cohort.
Discussion
Despite biologics being used increasingly for the treat-
ment of RA, their exact relationship with cancer still
TABLE 1 Baseline patient characteristics
Characteristic
sDMARD TNFi Rituximab
P-value(n= 159) (n = 243) (n = 23)
Age, mean (S.D.), years 66.1 (10.0) 62.7 (9.5) 67.3 (9.9) 0.0005
Sex, female, n (%) 118 (74.2) 199 (81.9) 15 (65.2) 0.058
DAS28, mean (S.D.) 5.2 (1.2) 6.6 (1.1) 6.5 (0) 0.0001
HAQ score, mean (S.D.) 1.7 (0.7) 2.2 (0.5) 2.1 (0.3) 0.0001
Disease duration, median (IQR), years 8 (318) 12 (618) 14 (531) 0.0047
Prior sDMARDs, median (IQR) 2 (24) 4 (36) 3 (25) 0.0001
RF+, n (%) 100 (62.9) 156 (64.2) 17 (73.9) 0.588
Steroid use at baseline, n (%) 50 (31.5) 123 (50.6) 13 (56.5) <0.001
Smoking, n (%) 0.050
Current 32 (20.4) 48 (19.9) 4 (17.4)
Ex 78 (49.7) 87 (36.1) 11 (47.8)
Never 47 (29.9) 106 (44.0) 8 (34.8)
Entry year, n (%) <0.001
Pre-2003 0 30 (12.4) 0
2003 10 (6.3) 68 (28.0) 0
2004 30 (18.9) 57 (23.5) 0
2005 44 (27.7) 30 (12.4) 0
2006 or after 75 (47.1) 58 (23.7) 23 (100)
Prior malignancy, n (%) 0.014
Solid 133 (83.7) 213 (87.7) 19 (82.6)
Lymphoproliferative 11 (6.9) 7 (2.9) 4 (17.4)
Melanoma 15 (9.4) 23 (9.4) 0 (0)
Time from most recent prior malignancy to registration
Median (IQR), years 7.9 (3.013.3) 11.5 (5.817.6) 5.4 (3.09.2) 0.0001
>10 years preregistration, n (%) 59 (37.1) 138 (56.8) 4 (17.4) <0.001
DAS28, Disease Activity Score 28; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; sDMARDS, synthetic
disease anti-rheumatic modifying drugs.
TABLE 2 Overall risk of new cancer
Total follow-up Censored at 5 years
DMARD
(n=159)
TNFi
(n = 243)
Rituximab
(n= 23)
DMARD
(n=159)
TNFi
(n = 243)
Rituximab
(n= 23)
Follow-up (py) 855 1591 81 609 971 81
Follow-up,
median (IQR),
years
6.6 (4.47.8) 6.8 (3.58.8) 3.9 (3.34.6) 5.0 (3.55.0) 5.0 (3.55.0) 3.9 (3.34.6)
Number of
first IMs
46 53 2 36 26 2
Rate/1000 py
(95% CI)
53.8 (39.4, 71.8) 33.3 (24.9, 43.6) 24.7 (3.0, 89.3) 59.1 (41.4, 81.9) 26.8 (17.5, 39.2) 24.7 (3.0, 89.3)
Unadjusted
HR (95% CI)
Ref. 0.51 (0.33, 0.79) 0.45 (0.11, 1.97) Ref. 0.45 (0.27, 0.75) 0.42 (0.10, 1.75)
Age and gender
adjusted
HR (95% CI)
Ref. 0.55 (0.35, 0.86) 0.43 (0.10, 1.80) Ref. 0.47 (0.28, 0.80) 0.41 (0.10, 1.71)
Age, gender and
smoking status
adjusted HR
(95% CI)
Ref. 0.56 (0.36, 0.88) 0.44 (0.11, 1.82) Ref. 0.48 (0.28, 0.81) 0.41 (0.10, 1.71)
IM, incident malignancy.
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remains unclear. The risk of cancer recurrence cannot be
explored in trials either, as patients with a prior malig-
nancy are systematically excluded. In this prospective ob-
servational cohort study, we have shown that in patients
with RA and prior malignancy selected to receive a TNFi or
RTX, the rate of first IM is not increased in comparison
with patients receiving sDMARDs. Nevertheless, attend-
ing to the wide confidence interval of the HR in the RTX
group, we cannot firmly rule out a clinically important
increased or decreased risk of IM in patients receiving
RTX.
The finding of a decreased rate of cancer incidence in
patients with a prior malignancy receiving a TNFi in com-
parison with biologic-naı¨ve patients is consistent with a
previous report from the BSRBR-RA [10], although the
present analysis extends the mean follow-up by 3 years.
A cumulative incidence plot in our original publication sug-
gested that the rate may accelerate with increasing dur-
ation of follow-up. Fortunately, we have observed that
after a median follow-up of the 6.8 years, there has
been no significant increase in the incidence of malignan-
cies in TNFi-treated patients. In this analysis, the small
number of each type of IM prevented us from analysing
specific cancers risk.
A major threat to the validity of our results is the poten-
tial confounding due to the non-randomization of treat-
ment. Patients’ baseline characteristics were unbalanced
between groups and some of these characteristics that
are associated with cancer recurrence risk may have influ-
enced treatment choices, particularly the choice to pro-
ceed with a biologic therapy. One of the most remarkable
differences between cohorts was the proportion of pa-
tients with a history of prior cancer as well as the time
from most recent prior malignancy to registration, which
was much shorter for patients starting RTX as their first
line biologic compared with both sDMARDs and TNFi.
There were also differences in the site of previous
cancer in those starting RTX, with a higher proportion of
prior lymphoma. These differences may have led to an
imbalance in the baseline risk of IM between the cohorts.
Finally, many of the patients who started RTX did so in
more recent years compared with those registered with
the TNFi cohort. What is not known is whether those pa-
tients starting RTX would have also started a TNFi if RTX
had not been available and therefore direct comparison of
risk between the two biologic treatment cohorts should
not be made.
Among RA patients, higher inflammatory activity is a
major risk determinant of cancer, particularly lymphoma.
On the other hand, no study has confirmed any treatment-
related effect on cancer [18, 19]. In our study, there was
also an imbalance in the disease activity measured by the
DAS28 and the severity measured by the HAQ score be-
tween the groups. Patients treated with TNFi and RTX had
significantly higher disease activity and disability than
those only receiving sDMARDs. Although at first it would
be expected that this imbalance increased the malignancy
rate in the biologic-treated patients, it could also be
hypothesized that the better control of the disease activity
achieved by biologic therapies may cause the opposite
effect. Details of disease activity and severity were not
available at all follow-up visits in all patients to explore
this further [20, 21].
Another possible difference between our cohorts is the
cancer screening at registration. Because biologic-treated
patients are registered with the BSRBR-RA at the initiation
of the biologic therapy, it is presumed that those patients
had some kind of cancer recurrence screening before they
started receiving the biologic therapy. This may not be
true for patients receiving sDMARD therapies. This may
explain in part why a higher rate of recurrence of the same
cancer was seen in the sDMARD cohort compared with
the TNFi cohort. There may also have been prognostic
factors associated with the prior cancer that led to a de-
cision not to start a biologic in certain patients, details
which were not captured in the BSRBR-RA.
One of the strengths of our cohort is its size and the
length of the follow-up, being the largest and longest
study to address this question to date. We also had
assumed near complete capture of prior cancers (the
one exception being if a cancer had been diagnosed
and treated in another country) and incident cancers
through linkage with the national cancer register and com-
prehensive physician and patient follow-up.
In conclusion, we have shown that after an average
follow-up of 5 years, patients with RA and prior malig-
nancy selected to receive treatment with either TNFi or
RTX in the UK do not have an increased risk of recurrence
or development of new IM. These results must be inter-
preted in the context of an observational study of routine
clinical practice.
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